Navigation Links
Genomenon and Nostos Genomics Partner to Accelerate Rare Genetic Disease Diagnoses

Genomenon® announced a partnership with Nostos Genomics, which includes integration of the Mastermind® Genomic Search Engine cloud-based AION variant interpretation platform. This integration will allow users of AION to preview the number of published articles related to their search and easily link out to view the evidence in Mastermind.

Leveraging genetic data and clinical evidence is the key to improving the diagnosis of rare diseases and making informed decisions with confidence. This integration of virtually all relevant literature into the genomic analysis process will empower clinical decision-makers to both maximize and act on profound insights contained in next generation sequencing data.

Mastermind connects patient genetic data with relevant evidence from scientific literature - an essential component of precision medicine for cancer and genetic disease. Using an AI-driven algorithm to index the full text of millions of genomic research articles, Mastermind has created a comprehensive database of over 7 million published variants across all genes and gene elements, updated on a weekly basis.

This innovative technology has positioned Mastermind as the world’s most comprehensive source for genomic literature in the variant interpretation space. Now integrated into over 20 clinical-grade decision support platforms across the globe, Mastermind has quickly become an ideal research companion for those tasked with decoding genomic data.

Nostos Genomics’ AION platform enhances genetic variant interpretation for clinical genetic testing by leveraging AI and functional genomics. Their white-box approach allows users to access a regularly updated knowledge repository with more than 100 annotations, including a selection of data from high-throughput functional genomics assays that directly reflect the molecular impact of thousands of selected mutations.

“This collaboration stemmed from a shared desire to not only provide clinicians with the best decision support possible, but also improve the accuracy, speed, and accessibility of genetic testing to lessen the burden of the diagnostic odyssey for patients,” said David Gorgan, CEO of Nostos Genomics. “The synergy of AION with Mastermind represents an exciting development for this important work.”

“We’re excited to partner with Nostos Genomics to put the most comprehensive and up-to-date genomic research in the hands of geneticists and researchers to accelerate rare disease diagnosis,” said Mike Klein, CEO of Genomenon. “Our relationship extends Mastermind’s global reach and connecting Mastermind with AION provides significant value in cutting turnaround time and increasing diagnostic yield for genetic testing labs.”

About Genomenon

Genomenon is an AI-driven genomics company that organizes the world’s genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer.

Genomenon was named Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.

For more information, visit

About Nostos Genomics

Nostos Genomics is a company engaged in the AI-driven deciphering of genetic diseases, translating genetic information into impactful clinical interventions. Its genetic variant interpretation platform AION leverages a combination of machine learning and functional genomics to characterize mutations and automate the interpretation.

For more information, visit:

Read the full story at

Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved

Related biology news :

1. Genomenon and Limbus Partner to Advance Genomic Variant Interpretation
2. Genomenon Accelerates Rare and Genetic Disease Research with Mastermind v2.0
3. Murrieta Genomics Subsidiary SimplSeq Files for Third Patent Designed to Improve DNA and RNA Sample Preparation
4. LabRoots’ Genetics Virtual Week Announces Three-Day Agenda for 2020 Event, Dedicated to Advancing Best Practices in Genomics, Molecular Diagnostics and Precision Medicine
5. Namocell, Takara Bio USA and HepaTx collaborate on single cell genomics analysis for cell therapy to treat late-stage liver diseases
6. Gateway Genomics Ranks No. 17 in the Inc. 5000 Series: California’s Fastest-Growing Private Companies for 2020
7. Murrieta Genomics To Host Genomic “Lunch’n’Learn” Event on February 25th
8. Gateway Genomics Ranks 236 in the Inc. 500 Fastest-Growing Private Companies in America List for 2019
9. Murrieta Genomics Welcomes Tx Genetic Research to Incubator
10. Gateway Genomics SneakPeek Noninvasive Prenatal Test (NIPT) Identifies Gender with Cell-free Fetal DNA from Microvolumes of Self-collected Maternal Blood
11. Murrieta Genomics To Sponsor SBIR/STTR Workshop - Entrepreneurs to Learn About “America’s Seed Fund”
Post Your Comments:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology: